Pixium Vision

Pixium Vision is developing retinal implant systems for patients who have lost their sight, with the intention of improving their vision and enabling them to lead more independent lives. The Company intends to harness the rapid advances being made in neural processing, micro-electronics and computing to develop retinal implant systems that for blind people could ultimately provide vision approaching that of a normal healthy Pixium's first device, IRIS1 (Intelligent Retinal Implantable System), uses an epi-retinal implant (on the retinal surface) and is currently in clinical trials with the goal of obtaining CE Mark. A second generation system (IRIS2) based on the same format, but offering better visual acuity and featuring several breakthrough technologies, is also under development. In addition, Pixium is developing a sub-retinal implant system (IRIS3), based on further technological breakthroughs, which has the potential to improve vision significantly compared to IRIS1 and IRIS2. Pixium was created in Paris, France in November 2011 as a spin-out of the Vision Institute and Université Pierre et Marie Curie, and based on collaborative work involving several leading academic teams across Europe. Pixium is backed by a syndicate of blue-chip European venture capital firms including Sofinnova Partners, Omnes Capital, Abingworth, Global Life Sciences Ventures, Seventure and Polytechnos.
Type
Public
HQ
Paris, FR
Founded
2011
Employees
37 (est)

Key People at Pixium Vision

Eric Le Joliff

Eric Le Joliff

Director, Operations
Bernard Gilly

Bernard Gilly

Founder, CEO & Board of Directors
Marcus Dapper

Marcus Dapper

Senior Development Engineer
Guillaume Buc

Guillaume Buc

CTO
Ralf Hornig

Ralf Hornig

Director, Clinical Affairs

Pixium Vision Locations

Paris, FR

Pixium Vision Metrics

Pixium Vision Summary

Founding Date

2011

Market capitalization

€70.1 M

Closing share price

€5.48

Pixium Vision Market Value History

Pixium Vision Online Presence

Pixium Vision News

Pixium Vision Company Life